Company / Capital Expenditures
Aligos Therapeutics, Inc. Capital Expenditures History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$130.0K
FY2024
5-year range
$130.0K / $2.1M
FY2020-FY2024
Trend
-86.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $892,000 to $130,000 over the past 2 years.
Based on SEC 10-K filings.
$130,000 in FY2024 with a 3-year CAGR of -60.2%.
Declined from $892,000 to $130,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -60.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -60.2%, indicating a declining trend.
- In FY2024, capital expenditures decreased 86.2% year-over-year.
- Peak capital expenditures was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $130.0K | -86.2% |
| FY2023 | $943.0K | +5.7% |
| FY2022 | $892.0K | -56.8% |
| FY2021 | $2.1M | -25.9% |
| FY2020 | $2.8M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026